GGHC
LFCR icon

Gilder Gagnon Howe & Co’s Lifecore Biomedical LFCR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-48,351
Closed -$639K – 249
2013
Q2 		$639K Buy
+48,351
New +$669K 0.01% 230

Other funds holding LFCR

GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gilder Gagnon Howe & Co's LFCR Position: Q3 2013 in Review

Gilder Gagnon Howe & Co sold out of Lifecore Biomedical (LFCR) in Q3 2013, closing a stake of 48,351 shares — an estimated $639K sold.

Gilder Gagnon Howe & Co first reported a position in LFCR in Q2 2013 and held it in 1 quarter. The position peaked at $639K in Q2 2013. 125 funds tracked by Wall St. Rank hold LFCR as of Q3 2013.

  • Gilder Gagnon Howe & Co reported no remaining Lifecore Biomedical position as of Q3 2013 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 48,351 Lifecore Biomedical shares in Q3 2013, an estimated $639K.
  • Gilder Gagnon Howe & Co first reported a position in Lifecore Biomedical in Q2 2013 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Lifecore Biomedical position peaked at $639K in Q2 2013.
  • 125 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2013.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2013, filed 12 Nov 2013.